Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) Shares Outstanding (Diluted Average) (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $1.0 million as the latest value for Q3 2024.

  • Quarterly Shares Outstanding (Diluted Average) fell 19.01% to $1.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Sep 2024, down 19.01% year-over-year, with the annual reading at $1.2 million for FY2023, 2.83% down from the prior year.
  • Shares Outstanding (Diluted Average) hit $1.0 million in Q3 2024 for Pasithea Therapeutics, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $24.4 million in Q3 2022 to a low of $1.0 million in Q1 2024.
  • Historically, Shares Outstanding (Diluted Average) has averaged $7.7 million across 4 years, with a median of $1.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 189.21% in 2022 and later crashed 94.72% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $10.4 million in 2021, then tumbled by 87.87% to $1.3 million in 2022, then decreased by 2.83% to $1.2 million in 2023, then fell by 14.87% to $1.0 million in 2024.
  • Business Quant data shows Shares Outstanding (Diluted Average) for KTTA at $1.0 million in Q3 2024, $1.0 million in Q2 2024, and $1.0 million in Q1 2024.